Guidance on Q13 Continuous Manufacturing of Drug Substances and Drug Products
The guidance is intended to build on the existing International Council for Harmonisation (ICH) quality guidance.
A new industry guidance, Q13 Continuous Manufacturing of Drug Substances and Drug Products, issued in March 2023 by FDA, explains the scientific and regulatory considerations for the development, implementation, operation, and lifecycle management of continuous manufacturing (CM). The guidance is intended to build on the existing International Council for Harmonisation (ICH) quality guidance and to provide clarification on CM concepts while further describing scientific approaches and regulatory considerations specific to CM of drug substances and drug products.
Further, the guidance applies to CM of drug substances and drug products for chemical entities and therapeutic proteins. It can be applicable to CM for new products, such as new drugs, generic drugs, and biosimilars, and for the conversion of batch manufacturing to CM for existing products.
Source: FDA
Texas' MD Anderson Cancer Center Creates New Cell Therapy Institute
November 11th 2024With the launch of the Institute for Cell Therapy Discovery and Innovation, the MD Anderson Cancer Center will bring together expertise in developing cell therapies for cancer, autoimmune diseases, and infections.
Novo Nordisk Hemophilia Treatment Gets Positive Opinion from CHMP
October 23rd 2024As many as 30% of people living with severe hemophilia A develop inhibitors such as TFPI, which can be produced by the body’s immune response to clotting factors in replacement therapy, often limiting the effectiveness of that therapy.
